The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels?
Abstract
Background — The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial showed that pravastatin significantly reduced mortality and coronary heart disease (CHD) events in 9014 patients with known CHD and total cholesterol 4.0 to 7.0 mmol/L at baseline. Secondary objectives included assessment of CHD event reduction according to lipid levels. Methods and Results — We investigated the relationships of baseline and on-study lipids with subsequent CHD events in separate Cox models. Treatment effect on CHD event reduction was examined by baseline lipids and after adjustment for on-study lipid levels. Baseline lipids were significant predictors of CHD events. The adjusted relative risk per mmol/L (on placebo) was 1.24 ( P =0.004) for total cholesterol, 1.28 ( P =0.002) for low-density lipoprotein cholesterol, and 0.52 ( P =0.004) for high-density lipoprotein cholesterol. Apolipoproteins A1 and B were strong predictors (each P =0.001). Pravastatin reduced the risk of the composite outcome of fatal CHD or nonfatal myocardial infarction by 24% (95% confidence interval [CI], 15% to 32%) and the expanded end point of fatal CHD, nonfatal myocardial infarction, unstable angina, or coronary revascularization by 17% (95% CI, 10% to 24%). Similar relative effects were observed for different categories of baseline lipids. The proportion of treatment effect explained by on-study lipid levels was 67% (95% CI, 27% to 106%) for the composite and 97% (95% CI, 49% to 145%) for the expanded end point. The most important lipids associated with event reduction were apolipoprotein B, low-density lipoprotein cholesterol, and the combination of total and high-density lipoprotein cholesterol. Conclusions — Changes in lipid levels can explain all or most of the observed benefit of pravastatin. Some treatment effect may also be mediated through nonlipid changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Measurement Error in Nonlinear Models
Carroll, R. J., Ruppert, D., & Stefanski, L. A. (1995) · Springer eBooks · doi:10.1007/978-1-4899-4477-1 · Cited by 1,749
Law, M. R., Wald, N. J., & Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.308.6925.367 · Cited by 1,210
Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Rosenson, R. S., & Tangney, C. C. (1998) · JAMA · doi:10.1001/jama.279.20.1643 · Cited by 954
Pekkanen, J., Linn, S., Heiss, G., Suchindran, C. M., Leon, A., Rifkind, B. M., & Tyroler, H. A. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006143222403 · Cited by 821
(1998) · Circulation · doi:10.1161/01.cir.97.15.1440 · Cited by 796
Statistical validation of intermediate endpoints for chronic diseases
Freedman, L. S., Graubard, B. I., & Schatzkin, A. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110204 · Cited by 651
Pedersen, T. R., Olsson, A. G., Færgeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyörälä, K., et al. (1998) · Circulation · doi:10.1161/01.cir.97.15.1453 · Cited by 621
Gotto, A. M., Whitney, E., Stein, E. A., Shapiro, D. R., Clearfield, M., Weis, S., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 563
The Value of Lowering Cholesterol after Myocardial Infarction
Rossouw, J. E., Lewis, B., & Rifkind, B. M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010183231606 · Cited by 410
Sacks, F. M., Tonkin, A. M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C. M., Keech, A., Packard, C., Simes, J., Byington, R., et al. (2000) · Circulation · doi:10.1161/01.cir.102.16.1893 · Cited by 388
Self-citationSacks, F. M., Moyé, L. A., Davis, B. R., Cole, T. G., Rouleau, J. L., Nash, D. T., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.97.15.1446 · Cited by 376
Serum Cholesterol as a Prognostic Factor after Myocardial Infarction: The Framingham Study
Wong, N. D., Wilson, P. W. F., & Kannel, W. B. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-687 · Cited by 192
Long-term risk stratification for survivors of acute coronary syndromes
Marschner, I. C., Colquhoun, D. M., Simes, R. J., Glasziou, P., Harris, P., Singh, B., Friedlander, D. H., White, H. D., Thompson, P., & Tonkin, A. M. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01360-2 · Cited by 129
Self-citationInfluence of baseline lipids on effectiveness of pravastatin in the CARE trial
Pfeffer, M. A., Sacks, F. M., Moyé, L. A., East, C. A., Goldman, S. M., Nash, D. T., Rouleau, J. R., Rouleau, J. L., Sussex, B. A., Théroux, P., et al. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00522-1 · Cited by 93
CHOLESTEROL-LOWERING TRIAL RESULTS IN THEIR EPIDEMIOLOGIC CONTEXT
Peto, R., Yusuf, S., & Collins, R. (1985) · Circulation · Cited by 89
Cited by
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Prepared by: British Cardiac Society, B. H. S. (2005) · Heart · doi:10.1136/hrt.2005.079988 · Cited by 1,216
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan, R. S. (2006) · Circulation · doi:10.1161/circulationaha.104.482570 · Cited by 1,212
Boekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., Simes, R. J., Durrington, P., Hitman, G. A., Welch, K. M. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.366 · Cited by 795
Self-citationLipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Diabetes Care · doi:10.2337/dc08-9018 · Cited by 707
Metadata
- Authors
- Simes, R. J., Marschner, I. C., Hunt, D., Colquhoun, D., Sullivan, D., Stewart, R. A. H., Hague, W., Keech, A., Thompson, P., White, H., Shaw, J., & Tonkin, A.
- Venue
- Circulation
- Published
- 2002-03-12
- Volume
- 105
- Issue
- 10
- Pages
- 1162-1169
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2097426078
- Cited by
- 254
- References
- 21
- FWCI
- 17.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.